Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1956 1
1958 1
1959 3
1960 1
1961 1
1962 1
1964 1
1965 2
1966 2
1967 5
1968 6
1969 3
1970 3
1971 3
1972 3
1973 4
1974 3
1975 4
1976 6
1977 2
1978 2
1979 4
1980 4
1982 4
1983 1
1984 3
1985 1
1986 2
1987 4
1988 2
1990 1
1991 4
1992 1
1993 2
1994 3
1995 3
1997 2
1998 1
1999 1
2000 1
2003 3
2004 1
2005 2
2006 4
2008 12
2009 4
2010 6
2011 9
2012 1
2013 2
2014 1
2015 4
2016 4
2019 2
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

155 results
Results by year
Filters applied: . Clear all
Page 1
Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery.
Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S, Knight R, Kunst G, Laing C, Nicholas J, Pepper J, Robertson S, Xenou M, Clayton T, Yellon DM; ERICCA Trial Investigators. Hausenloy DJ, et al. N Engl J Med. 2015 Oct 8;373(15):1408-17. doi: 10.1056/NEJMoa1413534. Epub 2015 Oct 5. N Engl J Med. 2015. PMID: 26436207 Free article. Clinical Trial.
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.
Mateo J, Moreno V, Gupta A, Kaye SB, Dean E, Middleton MR, Friedlander M, Gourley C, Plummer R, Rustin G, Sessa C, Leunen K, Ledermann J, Swaisland H, Fielding A, Bannister W, Nicum S, Molife LR. Mateo J, et al. Among authors: Bannister W. Target Oncol. 2016 Jun;11(3):401-15. doi: 10.1007/s11523-016-0435-8. Target Oncol. 2016. PMID: 27169564 Free article. Clinical Trial.
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
Robson M, Ruddy KJ, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Li W, Tung N, Armstrong A, Delaloge S, Bannister W, Goessl C, Degboe A, Hettle R, Conte P. Robson M, et al. Among authors: Bannister W. Eur J Cancer. 2019 Oct;120:20-30. doi: 10.1016/j.ejca.2019.06.023. Epub 2019 Aug 22. Eur J Cancer. 2019. PMID: 31446213 Free article.
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.
Rolfo C, de Vos-Geelen J, Isambert N, Molife LR, Schellens JHM, De Grève J, Dirix L, Grundtvig-Sørensen P, Jerusalem G, Leunen K, Mau-Sørensen M, Plummer R, Learoyd M, Bannister W, Fielding A, Ravaud A. Rolfo C, et al. Among authors: Bannister W. Clin Pharmacokinet. 2019 Sep;58(9):1165-1174. doi: 10.1007/s40262-019-00754-4. Clin Pharmacokinet. 2019. PMID: 30877569
A commercial transplant network's perspective of value in solid organ transplantation: Strategizing for value in transplant care.
Irwin FD, Wu C, Bannister WM, Bonagura AF, Laihinen B, Axelrod DA, Schnitzler MA. Irwin FD, et al. Among authors: Bannister WM. Transplant Rev (Orlando). 2016 Apr;30(2):71-6. doi: 10.1016/j.trre.2015.11.002. Epub 2016 Jan 8. Transplant Rev (Orlando). 2016. PMID: 26847615 Review.
The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results.
Podlekareva D, Bannister W, Mocroft A, Abrosimova L, Karpov I, Lundgren JD, Kirk O; EuroSIDA Study Group. Podlekareva D, et al. Among authors: Bannister W. Cent Eur J Public Health. 2008 Sep;16(3):99-105. Cent Eur J Public Health. 2008. PMID: 18935770 Free article. Review.
Economic value of a cancer case management program.
Wu C, Bannister W, Schumacker P, Rosen M, Ozminkowski R, Rossof A. Wu C, et al. Among authors: Bannister W. J Oncol Pract. 2014 May;10(3):178-86. doi: 10.1200/JOP.2014.001384. J Oncol Pract. 2014. PMID: 24839277
Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
Swaisland H, Plummer R, So K, Garnett S, Bannister W, Fabre MA, Dota C, Fielding A. Swaisland H, et al. Among authors: Bannister W. Cancer Chemother Pharmacol. 2016 Oct;78(4):775-84. doi: 10.1007/s00280-016-3124-5. Epub 2016 Aug 23. Cancer Chemother Pharmacol. 2016. PMID: 27553432 Clinical Trial.
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.
Dirix L, Swaisland H, Verheul HM, Rottey S, Leunen K, Jerusalem G, Rolfo C, Nielsen D, Molife LR, Kristeleit R, Vos-Geelen J, Mau-Sørensen M, Soetekouw P, van Herpen C, Fielding A, So K, Bannister W, Plummer R. Dirix L, et al. Among authors: Bannister W. Clin Ther. 2016 Oct;38(10):2286-2299. doi: 10.1016/j.clinthera.2016.08.010. Epub 2016 Oct 10. Clin Ther. 2016. PMID: 27745744 Clinical Trial.
155 results
Jump to page
Feedback